Skip to main content

Avance Clinical Featured in Endpoints News on Cell & Gene Therapy Capabilities

By November 25, 2021Company News

The cell and gene therapies (CGT) sector offers unprecedented opportunities for patient disease management across virtually all therapeutic areas. However, finding the right accredited clinical teams to take a therapy through to the clinic and manage the regulatory process can be a major challenge for biotechs with a CGT product.

According to a recent Global Data and the Alliance for Regenerative Medicine (ARM) report the sector raised a record $14bn in H1 2021, compared to $19.9bn for all of 2020.

The report also highlights that 2021 is on track to have the highest number of regulatory approvals of gene therapy and gene-modified cell therapy products, with Europe at risk of falling behind the US and Asia in terms of number of developers and new clinical trials.

Leave a Reply


DOWNLOAD OUR LATEST WHITEPAPER

Why 65% of US Biotechs Struggle to Identify Suitable CRO Partner

By filling in this form you consent to Avance Clinical contacting you. Read our Privacy Policy
This field is for validation purposes and should be left unchanged.

This will close in 0 seconds